Literature DB >> 579579

Detection of induced tumour-resistance to cyclophosphamide by the in vitro short term test.

M Volm, J Mattern, K Wayss.   

Abstract

Treatment of the solid Walker carcinosarcoma of the rat for a period of one year with cyclophosphamide (40 mg/kg at each passage; tumours were transplanted weekly) resulted in the formation of a cyclophosphamide-resistant tumour cell line. Without further treatment, animals injected with non-treated or cyclophosphamide pre-treated cells survived for 10 days on an average. After therapy with cyclophosphamide (2 x 38 mg/kg), rats with non-treated tumour cells survived 22 days whereas those with pre-treated tumours survived only for 17 days. Tumour cells which were shown to be sensitive in vivo also exhibited a larger reduction in 3H-thymidine and 3H-uridine incorporation in the in vitro short term test after incubation with urine from cyclophosphamide-treated rats or with 4-hydroperoxy-cyclophosphamide. The resistance to cyclophosphamide which was detected in animal experiments with Walker carcinosarcoma can therefore also be observed using the in vitro short term test.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 579579     DOI: 10.1007/bf00667365

Source DB:  PubMed          Journal:  Arch Gynakol        ISSN: 0003-9128


  29 in total

1.  Sensitivity tests of tumors to cytostatic agents. II. Investigation on human tumors.

Authors:  J Mattern; M Kaufmann; H Hinderer; K Wayss; M Volm
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1975

2.  Comparative chemotherapy studies on primary short-term cultures of human normal, benign, and malignant tumor tissues--a five-year study.

Authors:  J P COBB; D G WALKER; J C WRIGHT
Journal:  Cancer Res       Date:  1961-06       Impact factor: 12.701

3.  [Estimation of tumor sensitivity in vitro. II. Studies with the solid Ehrlich carcinoma of the mouse and the GW 77, a heterotransplanted human carcinoma].

Authors:  H J Seidel
Journal:  Z Krebsforsch       Date:  1970

4.  The effects of cytostatic drugs on transplanted tumours. An investigation of the correlation between in vivo and in vitro results.

Authors:  M Volm; J Mattern; K Wayss
Journal:  Arch Geschwulstforsch       Date:  1974

5.  [New possibilities in testing resistance of human carcinoma tissue to cytostatic agents in vivo].

Authors:  U Heckmann
Journal:  Dtsch Med Wochenschr       Date:  1967-05-19       Impact factor: 0.628

6.  [Rapid determination of DNA synthesis with 3H-thymidne].

Authors:  M Volm; R Spelhoff; R Süss
Journal:  Naturwissenschaften       Date:  1968-08

Review 7.  [Individual chemotherapy of solid tumors].

Authors:  M Volm; J Mattern
Journal:  Med Welt       Date:  1976-06-11

8.  [The evaluation of the cyclophosphamide sensitivity of human tumours by determining the incorporation of tritiated uridine and thymidine into the nucleic acids of human tumor cells in vitro in presence of 4-hydroxycyclophosphamide (author's transl)].

Authors:  G Bastert; H Schmidt-Matthiesen; G Voelcker; G Peter; H J Hohorst
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1975-09-22

9.  Sensitivity tests of tumors to cytostatic agents. I. Comparative investigations on transplanted tumors in vivo and in vitro.

Authors:  M Volm; M Faufmann; J MAttern; K Wayss
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1975

10.  Detection of induced resistance in short-term-tests. Adriamycin-resistant sarcoma 180.

Authors:  M Volm; C Lindner
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-01-26
View more
  2 in total

1.  [Detection of development of resistance in the short-term test (author's transl].

Authors:  M Volm; E Maass
Journal:  Blut       Date:  1979-10

2.  Chemosensitivity of human neoplasms with in vitro clone formation. Experience at the University of Southern California - Los Angeles County Medical Center.

Authors:  J R Daniels; A M Daniels; E E Luck; B Whitman; J T Casagrande; D G Skinner
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.